Exchange: NASDAQ·Updated 05:05 PM EDT
News
all
press releases
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Puma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines upcoming alisertib study milestones as Nerlynx sales climb.
Zacks
More News
Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates
Puma Biotech (PBYI) delivered earnings and revenue surprises of +90.00% and +6.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Puma Biotechnology Reports Second Quarter 2026 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2026. Unless otherwise stated, all comparisons are for the second quarter 2026 compared to the second quarter 2025. Product revenue, net consists entirely of...
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on August 3, 2026, the Compensation Committee of Pumas Board of Directors approved the grant of inducement restricted stock unit awards covering 35,375 shares of Puma common stock to five new non-executive...
Business Wire
Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline
Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, August 6, 2026, following the release of its second quarter 2026 financial results.The call may be accessed by dialing 1-877-709-8150 (domestic) or...
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 1, 2026, the Compensation Committee of Pumas Board of Directors approved the grant of inducement restricted stock unit awards covering 31,625 shares of Puma common stock to four new non-executive employees...
Business Wire
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why
PBYI's shares rally 19% in three months as rising Nerlynx demand and a raised 2026 revenue outlook boost investor confidence.
Zacks
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 1, 2026, the Compensation Committee of Pumas Board of Directors approved the grant of inducement restricted stock unit awards covering 7,000 shares of Puma common stock to two new non-executive employees...
Business Wire
PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Puma Biotechnology beats Q1 earnings and revenue estimates while raising its 2026 outlook.
Zacks

Advertisement|Remove ads.